Literature DB >> 30601091

Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.

Maria Ozerova1, Yulia Nefedova1.   

Abstract

Although the role of estrogen in solid cancers has been widely investigated, its effect in hematologic malignancies including multiple myeloma (MM) is not known. Here, we utilized a syngeneic mouse model of MM to address this question. In this model, treatment with 17β-estradiol significantly promoted progression of the disease. This effect has not been attributed to the direct effect of estrogen on MM cells but rather was mediated through estrogen-induced alterations in tumor microenvironment. In MM bone marrow, myeloid-derived suppressor cells (MDSCs) represent one of the major cellular populations. 17β-estradiol did not promote expansion and accumulation of MDSCs. However, it significantly increased their ability to suppress T cells proliferation. Thus, these data demonstrated that estrogen promotes progression of MM by enhancing an immunosuppressive function of the bone marrow MDSCs.

Entities:  

Keywords:  Estrogen; MDSC; immunosuppression; multiple myeloma; myeloid-derived suppressor cells; tumor microenvironment

Year:  2019        PMID: 30601091      PMCID: PMC6608706          DOI: 10.1080/10428194.2018.1538511

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Estrogen receptors in human myeloma cells.

Authors:  T Otsuki; O Yamada; J Kurebayashi; T Moriya; H Sakaguchi; H Kunisue; K Yata; M Uno; Y Yawata; A Ueki
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

2.  Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.

Authors:  E Van Valckenborgh; E Schouppe; K Movahedi; E De Bruyne; E Menu; P De Baetselier; K Vanderkerken; J A Van Ginderachter
Journal:  Leukemia       Date:  2012-04-23       Impact factor: 11.528

Review 3.  Membrane estrogen receptor regulation of hypothalamic function.

Authors:  Paul E Micevych; Martin J Kelly
Journal:  Neuroendocrinology       Date:  2012-09-14       Impact factor: 4.914

Review 4.  Angiogenesis in multiple myeloma.

Authors:  Christian Jakob; Jan Sterz; Ivana Zavrski; Ulrike Heider; Lorenz Kleeberg; Claudia Fleissner; Martin Kaiser; Orhan Sezer
Journal:  Eur J Cancer       Date:  2006-06-23       Impact factor: 9.162

Review 5.  Bone marrow angiogenesis in multiple myeloma.

Authors:  A Vacca; D Ribatti
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

6.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors.

Authors:  Robert Suriano; Devyani Chaudhuri; Raja Singh Johnson; Erin Lambers; Badithe T Ashok; Raj Kishore; Raj K Tiwari
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

8.  Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.

Authors:  Wan Cheung Cheung; Joong Su Kim; Michael Linden; Liangping Peng; Brian Van Ness; Roberto D Polakiewicz; Siegfried Janz
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

9.  Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature.

Authors:  Sabine Olivier; Pierre Close; Emilie Castermans; Laurence de Leval; Sebastien Tabruyn; Alain Chariot; Michel Malaise; Marie-Paule Merville; Vincent Bours; Nathalie Franchimont
Journal:  Mol Pharmacol       Date:  2006-02-23       Impact factor: 4.436

10.  Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.

Authors:  Kevin D Boyd; Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Zoe J Konn; William J Tapper; Brian A Walker; Christopher P Wardell; Walter M Gregory; Alex J Szubert; Faith E Davies; Gareth J Morgan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-15       Impact factor: 4.254

View more
  5 in total

1.  Involvement of impaired CD8+ mucosal-associated invariant T cells and myeloid-derived suppressor cells in polycystic ovary syndrome.

Authors:  Mengting Zhu; Yuping Xu; Caihua Li; Zhimin Lu; Kaihuan Bi; Kangxia Wang; Peipei Guo; Huanhuan Jiang; Yunxia Cao
Journal:  Reprod Biol Endocrinol       Date:  2021-11-30       Impact factor: 5.211

2.  Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Vicky C Chang; Ali A Khan; Wen-Yi Huang; Hormuzd A Katki; Mark P Purdue; Ola Landgren; Jonathan N Hofmann
Journal:  Blood Cancer J       Date:  2022-04-01       Impact factor: 11.037

Review 3.  Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin.

Authors:  Shunjie Yu; Xiaotong Ren; Lijuan Li
Journal:  Exp Hematol Oncol       Date:  2022-07-19

Review 4.  Sex steroid hormone function in the brain niche: Implications for brain metastatic colonization and progression.

Authors:  María J Contreras-Zárate; Diana M Cittelly
Journal:  Cancer Rep (Hoboken)       Date:  2020-03-03

5.  Human Leucocyte Antigen G and Murine Qa-2 Are Critical for Myeloid Derived Suppressor Cell Expansion and Activation and for Successful Pregnancy Outcome.

Authors:  Stefanie Dietz; Julian Schwarz; Ana Velic; Irene González-Menéndez; Leticia Quintanilla-Martinez; Nicolas Casadei; Alexander Marmé; Christian F Poets; Christian Gille; Natascha Köstlin-Gille
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.